Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer
Lung Cancer
Explore 299 assets in Lung Cancer →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Daiichi Sankyo
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02134015CT.gov Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer (this asset) | Daiichi Sankyo | P3 | CC · 45 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 53 |
| Triple-Negative Breast Carcinoma | — | P2 | CC · 46 |
| Angiosarcoma | — | P2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-neuregulin-receptor-her3-human-monoclonal-u3-1287-heavy-chain-disulfide-with-human-monoclonal-u3-1287-chain-dimer-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →